Document resource
A crucial study that enabled the vasculitis drug avacopan, branded as Tavneos, to gain regulatory approval has been retracted by the New England Journal of Medicine (NEJM).1
Annotated abstract
Trial paper is retracted as FDA keeps scrutiny on controversial vasculitis drug
bmj · 2026-07-08 · canonical JSON source